In a study by Tan and colleagues, the expression of PD-L1 in CTCs from 155 patients with different advanced tumor types was assessed to investigate its role in predicting and monitoring the response to PD-1/PD-L1 blockade immunotherapies. Here, CD274 is linked to neoplasm.